Kane Biotech Inc., a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms today announces the Company has entered into an option agreement with a Global Health Care Company who has been assessing some of Kane Biotech’s antibiofilm and antimicrobial technologies for use in the animal heath market.
Under the terms of the agreement, the Health Care Company will now complete their due diligence surrounding Kane’s technology with an option to obtain an exclusive, worldwide license to develop, commercialize and market certain oral care and wound care technologies in the global animal health market.
“Our strategy is to license our technology to industry leaders and we are pleased with this development in the animal health market” commented Gord Froehlich, President and CEO of Kane Biotech. “This is an excellent strategic fit and we are very excited to establish a strong collaboration between our organizations in providing innovative biofilm solutions to the animal health market worldwide”.
Details of the agreement are confidential.